Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04028960
Other study ID # A16-716
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date October 23, 2019
Est. completion date April 8, 2020

Study information

Verified date May 2020
Source HealthPartners Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine how Humulin-R regular insulin affects the body's ability to feel low blood sugar (hypoglycemia) when delivered intranasally compared to placebo in subjects with Type 1 Diabetes (T1D) with hypoglycemia awareness. The study will use continuous glucose monitoring (CGM) to collect this information. The study drug or placebo will be administered using an intranasal device.


Description:

Hypoglycemia occurs with high frequency among patients with T1D. With repeated episodes of hypoglycemia, the counter-regulatory pathways to restore normal glucose are blunted, and patients can become unaware of the hypoglycemia. It is estimated that 40% of patients with T1D have hypoglycemia unawareness. The study has the following objectives: 1. Primary: a. To assess non-inferiority of dangerous hypoglycemia with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia. 2. Secondary: 1. To describe changes in overall glycemic control with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia 2. To describe changes in hypoglycemia awareness with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia 3. To describe changes in safety endpoints with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia. 3. Exploratory: 1. To describe changes in memory, attention and executive function with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date April 8, 2020
Est. primary completion date April 8, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (age =18) with type 1 diabetes diagnosis and a duration of diabetes of at least 10 years - Gold score <4 - HbA1c =6.5% within the last 3 months or at screen visit - Stable insulin regimen (MDI or insulin pump) for at least 3 months, as deemed stable by principal investigator - Depression/anxiety medications stable for at least 3 months - Ability and willingness to wear CGM continuously during study participation - Participants must use their own smartphone, and have the ability and willingness to use CGM smartphone applications compatible with their smartphone - Ability and willingness to check self-monitoring of blood glucose (SMBG) using own supplies, as instructed by study staff - Ability and willingness to document when having symptoms of hypoglycemia in the CGM smartphone app or in a diary - Willing to operate insulin pump without threshold suspend feature or hybrid closed-loop, if applicable - Proficient in speaking, reading and understanding English in order to complete surveys and testing of cognitive function - Women of child-bearing age must agree to procure and use contraception throughout the study Exclusion Criteria: - Pregnancy or planning pregnancy - eGFR = 30 mL/min per 1.73 m2, if available from medical record - Completed any other research study within 6 months of screening date - Current or recent use within 3 months of an insulin delivery system that adjusts insulin in response to continuous glucose monitoring (CGM) data (such as an automated insulin delivery system like hybrid closed-loop insulin pump therapy) - Known dementia or mild cognitive impairment diagnosis - Diabetic ketoacidosis within the last 6 months - Use of non-insulin medications to treat diabetes - Those planning to change diet or exercise regimen during the study - History of trans-sphenoidal surgery or surgery to the upper part of the nasal cavity, chronic sinusitis, severe deviated septum, or difficulty with smell and/or taste - Severe psychiatric illness - Allergy to adhesives, insulin or any components of insulin product - Subject cannot adequately demonstrate ability to use and deploy the devices as determined by investigator - Evidence of suicidality using the Columbia-Suicide Severity Rating Scale (C-SSRS) - Subject has history of any of the following: moderate to severe pulmonary disease, poorly controlled congestive heart failure, significant cardiovascular and/or cerebrovascular events within previous 6 months, condition known to affect absorption, distribution, metabolism, or excretion of drugs such as any hepatic, renal or gastrointestinal disease or any other clinically relevant abnormality or illness that inclusion would pose a safety risk to the subject as determined by investigator.

Study Design


Intervention

Drug:
Regular insulin (Humulin-R), intranasal route
Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
Device:
SipNose intranasal device
The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.

Locations

Country Name City State
United States Health Partners Institute dba International Diabetes Center Minneapolis Minnesota

Sponsors (3)

Lead Sponsor Collaborator
HealthPartners Institute International Diabetes Center at Park Nicollet, Juvenile Diabetes Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Time With Dangerous Hypoglycemia Defined using percent time below range (<54 mg/dL), from real-time continuous glucose monitoring (CGM) Two 14-20 day treatment periods
Secondary Percent of Time With Blood Glucose 70-180 mg/dL Defined using percent of Blood Glucose 70-180 mg/dL from real-time continuous glucose monitoring (CGM) Two 14-20 day treatment periods
Secondary Percentage of Time With Blood Glucose <70 mg/dL Defined using percent of Blood Glucose <70 mg/dL from real-time continuous glucose monitoring (CGM) Two 14-20 day treatment periods
Secondary Percentage of Time Blood Glucose >180 mg/dL Percentage of time Blood Glucose >180 mg/dL from real-time continuous glucose monitoring (CGM) Two 14-20 day treatment periods
Secondary Percentage of Time With Blood Glucose >250 mg/dL Percentage of time with Blood Glucose >250 mg/dL from real-time continuous glucose monitoring (CGM) Two 14-20 day treatment periods
Secondary Percentage of Time Participant Had Active Sensor Wear Percentage of time Participant had Active Sensor Wear from real-time continuous glucose monitoring (CGM) Two 14-20 day treatment periods
Secondary Mean Glucose From the Study Participants Mean Glucose from the Study Participants from real-time continuous glucose monitoring (CGM) Two 14-20 day treatment periods
Secondary Coefficient of Variation (%CV) of Blood Glucose Values From CGM Data The Coefficient of variation was calculated by dividing the standard deviation of blood glucose values by the mean of the blood glucose values based on data from the corresponding CGM readings. Two 14-20 day treatment periods
Secondary Glucose Management Indicator (GMI) An approximate HbA1c based upon real-time continuous glucose monitoring (CGM) values Two 14-20 day treatment periods
See also
  Status Clinical Trial Phase
Completed NCT03886974 - Transition to Adult Care in Type 1 Diabetes
Completed NCT05620251 - Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Active, not recruiting NCT05078658 - Low-carbohydrate Diet in Children With Type 1 Diabetes N/A
Not yet recruiting NCT06018324 - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Withdrawn NCT03736083 - Introducing CGM at Type 1 Diabetes Diagnosis N/A
Completed NCT03177096 - Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes N/A
Not yet recruiting NCT06418269 - The Effect of Therapeutic Play on Anxiety and Fear Levels in Children With Diabetes N/A
Completed NCT04172077 - Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
Recruiting NCT04950634 - Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
Completed NCT04450745 - Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients N/A
Completed NCT03165786 - A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes N/A
Recruiting NCT05324488 - Diabetes Registry Graz for Biomarker Research
Completed NCT02984709 - Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes N/A
Completed NCT02984514 - Brown Adipose Tissue in Type 1 Diabetes N/A
Recruiting NCT06372392 - Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps N/A
Recruiting NCT05973799 - Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes N/A
Recruiting NCT03311516 - New Insulin Therapy by Multiwave Bolus N/A
Completed NCT03711656 - Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques N/A
Recruiting NCT05737654 - The Effect of Exercise on Metabolic Parameters, Anthropometric Measurement Values and Quality of Life N/A